EphA2/EGFR Dual-Targeting Dual-Payload 2by2 ADC for Precision Cancer Therapy to Overcome Tumor Heterogeneity and Drug Resistance
Technology Introduction:
EE-CMab 2by2 ADC is a novel dual-targeting, dual-payload bispecific antibody-drug conjugate. By simultaneously recognizing EphA2 and EGFR, it precisely delivers MMAE and Exatecan. Combining tumor-selective targeting with multi-mechanistic cytotoxicity, this platform provides a breakthrough strategy to overcome tumor heterogeneity and drug resistance in cancer therapy.
Industrial Applications:
EE-CMab 2by2 ADC addresses tumor heterogeneity and drug resistance through its innovative dual-targeting (EphA2/EGFR) and dual-payload (MMAE/Exatecan) architecture. This modular platform enhances therapeutic coverage and multi-mechanistic cytotoxicity. With strong First-in-class potential, it is optimized for global out-licensing and commercialization, positioning it as a leader in the next-generation precision oncology market.
Taipei Medical University
Taipei Medical University (TMU), established in 1960, is a comprehensive university in Taipei focusing on medicine and health sciences. It offers colleges in medicine, pharmacy, dentistry, nursing, and more. TMU is dedicated to advancing medical research, clinical practice, and interdisciplinary collaboration while fostering global engagement and training professional healthcare talents.
Contact Information
Name：Chang, Fu-Ling
Tel：02-2736-1661 #24005
Address：No. 250, Wuxing St., Xinyi Dist., Taipei City 110301, Taiwan (R.O.C.)
